Michael Kauffman (CEO, Karyopharm)
Karyopharm bags an upset win at the FDA as regulators OK myeloma drug despite a host of objections
Somebody high up at the FDA must really like Karyopharm $KPTI.
On Wednesday the biotech announced that the agency had stamped an OK on their …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
